Author/Editor		Hochmair, Maximilian J; Morabito, Alessandro; Hao, Desiree; Yang, Cheng-Ta; Soo, Ross A; Yang, James C-H; Gucalp, Rasim; Halmos, Balazs; Märten, Angela; Čufer, Tanja
Title		Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Type		članek
Vol. and No.		Letnik 16, št. 34
Publication year		2020
Volume		str. 2799-2808
ISSN		1744-8301 - Future oncology (London, England)
Language		eng
Abstract		Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment >/=10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients.
Descriptors		Carcinoma, non-small cell lung Drug therapy Afatinib Nedrobnocelični karcinom pljuč Terapija z zdravili Afatinib Therapy Terapija
Keywords		osimertinib raziskava GioTag osimertinib GioTag study